48.84

2.22% +1.06

Praxis Precision Medicines Inc (PRAX)

Overview News Price History Option Chain Discussions Forecast

Praxis Precision Medicines Inc stock is currently priced at $48.84, with a 24-hour trading volume of 246.52K. It has seen a +2.22% increased in the last 24 hours and a -9.34% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $47.62 pivot point. If it approaches the $50.18 resistance level, significant changes may occur.

Previous Close:

$47.78

Open:

$47.96

24h Volume:

246.52K

Market Cap:

$834.57M

Revenue:

Net Income/Loss:

$-123.28M

P/E Ratio:

-16.12

EPS:

-3.03

Net Cash Flow:

$-111.14M

1W Performance:

-6.81%

1M Performance:

-9.34%

6M Performance:

+4,261%

1Y Performance:

+4,464%

1D Range:

$47.96

$50.43

52W Range:

$0.83

$67.21

Praxis Precision Medicines Inc Stock (PRAX) Company Profile

Name

Praxis Precision Medicines Inc

Sector

Healthcare (1196)

Industry

Biotechnology (685)

Phone

617 300 8460

Address

99 High Street, 30th Floor, Boston

Employee

109

Twitter

Next Earnings Date

2024-05-09

Latest SEC Filings

PRAX's Discussions on Twitter

Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-19-23	Initiated	Truist	Buy
Jun-06-22	Downgrade	Wedbush	Outperform → Neutral
Dec-16-21	Initiated	H.C. Wainwright	Buy
Aug-26-21	Initiated	BofA Securities	Buy
Apr-26-21	Initiated	William Blair	Outperform
Nov-11-20	Initiated	Wedbush	Outperform
Nov-10-20	Initiated	Cowen	Outperform
Nov-10-20	Initiated	Evercore ISI	Outperform
Nov-10-20	Initiated	Piper Sandler	Overweight

View All

Praxis Precision Medicines Inc Stock (PRAX) Latest News

Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting

GlobeNewswire Inc.

Praxis Precision Medicines (PRAX) Upgraded to Buy: Here's Why

Zacks Investment Research

Praxis Precision Medicines to Participate in Upcoming April Conferences

GlobeNewswire Inc.

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

Biotech Stock Roundup: PRAX, VKTX Up on Study Results & MRNA, REGN Give Updates

Zacks Investment Research

Praxis Precision Medicines, Inc. Announces Pricing of $200 Million Public Offering

GlobeNewswire Inc.

Praxis Precision Medicines Inc Stock (PRAX) Financials Data

Praxis Precision Medicines Inc (PRAX) Net Income 2024

PRAX net income (TTM) was -$123.28 million for the quarter ending December 31, 2023, a +42.40% increase year-over-year.

Praxis Precision Medicines Inc (PRAX) Cash Flow 2024

PRAX recorded a free cash flow (TTM) of -$111.14 million for the quarter ending December 31, 2023, a +40.08% increase year-over-year.

Praxis Precision Medicines Inc (PRAX) Earnings per Share 2024

PRAX earnings per share (TTM) was -$22.59 for the quarter ending December 31, 2023, a +67.68% growth year-over-year.

Praxis Precision Medicines Inc Stock (PRAX) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
DeSimone Jill	Director	Oct 05 '23	Buy	1.75	14,500	25,375	14,500
Souza Marcio	Chief Executive Officer	Jun 27 '23	Buy	1.06	10,000	10,587	45,002

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase IIb clinical trial for the treatment of essential tremor, as well as in Phase II clinical trial to treat Parkinson's disease; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. Praxis Precision Medicines, Inc. was incorporated in 2015 and is based in Boston, Massachusetts.